Rivanol (ethacridine lactate veterinary-grade API) is a synthetic acridine derivative supplied as a yellow crystalline powder for downstream processing into tablets, capsules, injections, powders, granules, premixes, and solutions. The substance is light-sensitive; aqueous preparations should be manufactured under sodium-vapour or low-UV lighting. The following application scenarios are separated by dosage form because each route imposes distinct constraints on pH, moisture, and terminal processing. Where published data for a specific configuration are limited, that limitation is stated rather than extrapolated from small-molecule behaviour. This document is limited to manufacturing and formulation parameters; it does not replace species-specific regulatory review.

Intrauterine lavage solutions for cattle represent a documented downstream use in markets where ethacridine lactate is listed for veterinary antiseptic irrigation. The API is dissolved in water for injection at 0.05% w/v to 0.1% w/v; concentrations above 0.2% w/v are generally avoided because local tissue irritation may increase, although published species-specific tolerance data are limited. Dissolution is carried out at 45–50 °C in a jacketed stainless steel vessel with bottom-mounted magnetic stirring. Final pH is adjusted to 4.5–5.5 using dilute lactic acid; citrate buffers are preferred over phosphate because phosphate systems may reduce solubility at low storage temperatures, though published data for this specific combination are limited. The product is cooled to 20–25 °C, filtered through a 0.22 µm PVDF membrane, and filled into amber Type I glass bottles under nitrogen overlay. Sterile filtration is preferred over terminal steam sterilization at 121 °C because prolonged heat can intensify yellow discoloration and increase related substances. The processing line must be free of hypochlorite residues; alkaline cleaning agents are followed by rinsing with 0.1 N citric acid to prevent acridine base precipitation on tank walls. A clean-in-place spray ball at 2.5 bar for 10 min is specified after every batch; batch-to-batch carryover of yellow film on O-rings has been observed on production lines when rinse water exceeds 60 °C. The finished solution is labeled for protected storage and used with sterile catheters; no systemic efficacy claim is made.

What Limits Terminal Sterilization of Ethacridine Lactate Injection Solutions?

Injectable presentations of ethacridine lactate are constrained by the same photochemical and pH sensitivity. The pH of the injection solution is maintained at 4.0–5.5; above 6.8 free base precipitation can occur, but published data for this specific configuration is limited. Terminal steam sterilization at 121 °C for 15 min may generate acridine-related impurities; the common industrial alternative is aseptic filtration through 0.22 µm PVDF. Subvisible particle testing follows USP<788> for small-volume injectables or Ph. Eur. 2.9.19. Tonicity is adjusted with dextrose rather than sodium chloride where solubility in saline is not fully documented. Filling under nitrogen in amber ampoules reduces oxidative color change. Rubber closures should be coated bromobutyl because sulfur-vulcanized elastomers can release extractables that complex with basic acridine groups. Container closure integrity is tested according to USP<1207>. Long-term storage above 25 °C shortens shelf life; cold storage may cause crystals to form, which must redissolve by gentle warming to 37 °C before use. Injectable products are not intramuscular or intravenous systemic therapies in most regulated markets; they are intended for irrigation or local lavage where approved. This route requires sterile API with endotoxin controlled below 0.5 EU/mg when used in large-volume irrigation devices, though published data for ethacridine lactate endotoxin levels are limited.

Wound irrigation and topical powders for livestock are prepared from the same API but with less restrictive compendial requirements. Dilute solutions at 0.05% w/v to 0.2% w/v are filled into non-sterile squeeze bottles for field use. The raw powder is pre-sieved through a 630 µm mesh to remove crystal clusters. For dry wound powders, ethacridine lactate is combined with lactose monohydrate or light kaolin by geometric dilution in a V-blender. The active concentration in wound powder is normally 0.1% w/w to 0.5% w/w. Blending at 50% fill volume and 15 rpm for 15 min yields a homogeneous yellow powder; higher speeds generate undesirable dust and static adhesion to stainless steel surfaces. The powder is packaged in low-moisture sachets because acridine wetting causes dark spots. Topical powders must not be mixed with hypochlorite or iodine-releasing agents; oxidative degradation may discolor the product and reduce available active. Published compatibility data for these combinations are limited. If the powder is intended for application to open wounds, microbial limits follow Ph. Eur. 5.1.4 for non-sterile aqueous and solid products; treated batches above 10³ CFU/g TAMC are rejected.

When Direct Compression Replaces Wet Granulation in Ethacridine Lactate Tablets

Oral tablets for calf and piglet enteric antiseptic applications are produced by either direct compression or wet granulation where authorized. Direct compression is feasible only when the active dose per tablet is at least 5 mg and the API has been milled to a D90 below 150 µm. Unmilled needle-shaped crystals have flow function coefficients below 4 and bridge in feed hoppers. A direct compression premix might contain 30% w/w microcrystalline cellulose, 58% w/w lactose monohydrate, 0.5% w/w colloidal anhydrous silica, and 0.5% w/w magnesium stearate. The mixture is blended for 12 min in a low-shear tumble blender at 12 rpm. For low-dose formulations below 5 mg, wet granulation with polyvinylpyrrolidone K30 at 3% w/w is specified. Granulation in a top-spray fluid bed with inlet air at 55–60 °C and product moisture below 2.0% w/w prevents API migration to granule surfaces. Final tablets are compressed to hardness 5–7 kp on a rotary press with B tooling. Friability is kept below 1.0% after 100 revolutions. Content uniformity must meet USP<905> acceptance value ≤15.0. Dissolution testing, where required by the destination authority, may use USP Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid; a harmonized veterinary dissolution specification is not published for this API. Tablets are packed in amber PVC/PVDC blisters because direct sunlight converts the yellow tablets to brown within weeks. The production area should use local exhaust over the compression feed hopper to prevent yellow dust from contaminating adjacent lines.

Drinking-water powders, granules, and medicated premixes form a separate downstream category because feed matrices introduce additional stability and homogeneity risks. For water-dispersible granules, the API is mixed with lactose, sodium citrate, and a nonionic wetting agent; the blend is granulated in a fluidized-bed system with inlet air at 55 °C to a mass mean diameter of 150–400 µm. Granules outside this range either float or settle too rapidly in drinking water. Dispersion time at 20 °C should be below 3 min when added to water under gentle stirring. Final drinking-water concentrations are normally between 0.01% w/v and 0.05% w/v; higher levels may cause reduced palatability, though published data for this specific configuration are limited. Premix production in a horizontal ribbon blender must achieve an assay coefficient of variation below 5.0% after 10 min; batch-to-batch variance increases when API is added directly to mineral carriers without a preblend step. Mineral carriers such as calcium carbonate may raise the microenvironmental pH, promoting free base precipitation and uneven distribution. Organic carriers such as ground corn cob or lactose are preferred. Cleaning after batches requires acidified rinse solution, because alkaline cleaning can leave a fluorescent yellow residue on contact surfaces that is detectable by UV inspection. Carryover in subsequent non-medicated feed batches is monitored by HPLC with a LOQ below 0.1 ppm. Premixes should be stored in opaque, moisture-resistant bags at or below 25 °C and protected from condensation; lumping has been observed when warehouse relative humidity exceeds 60%.

Udder Hygiene and Teat Dip Concentrate Constraints

Concentrated teat dip formulations based on ethacridine lactate are prepared as aqueous solutions at 0.1% w/v to 0.3% w/v. The active is introduced before film-forming polymers because acridine yellow can otherwise become trapped in polymer micelles and reduce visual homogeneity. Polyvinylpyrrolidone and polyvinyl alcohol are compatible with the API under moderate shear at pH 4.0–4.5. High-shear homogenization above 3000 rpm is unnecessary and may entrain air; low-shear mixing for 20 min is sufficient. The final dip is filled into opaque containers and used within 24 h of opening in field conditions. Teat dip concentrates must not be blended with chlorhexidine gluconate or iodine-based antiseptics because co-precipitation and color changes have been reported, although published compatibility data are limited. The product should be rejected if the color shifts from yellow to orange-brown, as this may indicate oxidative degradation. Rinse water from cleaning should be sampled for UV absorbance at 254 nm to monitor residual acridine in dairy equipment. This application is subject to local milk withdrawal rules; no harmonized MRL applies in all markets.

Capsule dosage forms for individual animal administration are produced by filling a preblended mixture of ethacridine lactate and lactose monohydrate into hard gelatin or HPMC shells. For active loads below 10 mg, direct fill causes unacceptable weight variation; a trituration step with lactose is required to improve dose accuracy. The milled API is controlled to D90 below 100 µm because larger crystals stick to the tamping pins of semi-automatic capsule fillers and cause weight drift. Filling machine contact surfaces should be hard-chrome or Teflon-coated to reduce yellow staining. Capsule shells are sealed and packed in amber glass bottles with desiccant. Disintegration testing in pH 1.2 simulated gastric fluid at 37 °C follows Ph. Eur. 2.9.1; capsules should disintegrate within 15 min. Enteric coating is not recommended because published data for delayed release of ethacridine lactate are absent. Capsule formulations containing effervescent salts are avoided; the resulting pH spike can precipitate the free base inside the shell. Batch-release data usually include assay, uniformity, and moisture. Residual dust from capsule filling is collected by local exhaust and not recirculated.